These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 10232587)

  • 21. [Inhibitors of isoprenylation of ras p21].
    Yoshimatsu K
    Gan To Kagaku Ryoho; 1997 Sep; 24(11):1495-502. PubMed ID: 9309147
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Raf and RhoA cooperate to transform intestinal epithelial cells and induce growth resistance to transforming growth factor beta.
    Du J; Jiang B; Coffey RJ; Barnard J
    Mol Cancer Res; 2004 Apr; 2(4):233-41. PubMed ID: 15140945
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The farnesyltransferase inhibitor, LB42708, inhibits growth and induces apoptosis irreversibly in H-ras and K-ras-transformed rat intestinal epithelial cells.
    Kim HS; Kim JW; Gang J; Wen J; Koh SS; Koh JS; Chung HH; Song SY
    Toxicol Appl Pharmacol; 2006 Sep; 215(3):317-29. PubMed ID: 16712893
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High affinity for farnesyltransferase and alternative prenylation contribute individually to K-Ras4B resistance to farnesyltransferase inhibitors.
    Fiordalisi JJ; Johnson RL; Weinbaum CA; Sakabe K; Chen Z; Casey PJ; Cox AD
    J Biol Chem; 2003 Oct; 278(43):41718-27. PubMed ID: 12882980
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB.
    Du W; Lebowitz PF; Prendergast GC
    Mol Cell Biol; 1999 Mar; 19(3):1831-40. PubMed ID: 10022870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reversion of a human tumour cell line containing oncogenic p21ras is associated with a defect in the post-translational processing of the ras protein.
    Tilbrook PA; Paterson HF; Marshall CJ
    Oncogene; 1995 Feb; 10(4):805-9. PubMed ID: 7862461
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ras farnesyltransferase inhibition: a novel and safe approach for cancer chemotherapy.
    Nammi S; Lodagala DS
    Acta Pharmacol Sin; 2000 May; 21(5):396-404. PubMed ID: 11324435
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Arglabin-DMA, a plant derived sesquiterpene, inhibits farnesyltransferase.
    Shaikenov TE; Adekenov SM; Williams RM; Prashad N; Baker FL; Madden TL; Newman R
    Oncol Rep; 2001; 8(1):173-9. PubMed ID: 11115593
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The farnesyltransferase inhibitor, FTI-2153, inhibits bipolar spindle formation during mitosis independently of transformation and Ras and p53 mutation status.
    Crespo NC; Delarue F; Ohkanda J; Carrico D; Hamilton AD; Sebti SM
    Cell Death Differ; 2002 Jul; 9(7):702-9. PubMed ID: 12058275
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects.
    Feldkamp MM; Lau N; Guha A
    Oncogene; 1999 Dec; 18(52):7514-26. PubMed ID: 10602510
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor.
    Omer CA; Chen Z; Diehl RE; Conner MW; Chen HY; Trumbauer ME; Gopal-Truter S; Seeburger G; Bhimnathwala H; Abrams MT; Davide JP; Ellis MS; Gibbs JB; Greenberg I; Koblan KS; Kral AM; Liu D; Lobell RB; Miller PJ; Mosser SD; O'Neill TJ; Rands E; Schaber MD; Senderak ET; Oliff A; Kohl NE
    Cancer Res; 2000 May; 60(10):2680-8. PubMed ID: 10825141
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors.
    Du W; Prendergast GC
    Cancer Res; 1999 Nov; 59(21):5492-6. PubMed ID: 10554025
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Suppression of tumorigenicity in Ras-transformed fibroblasts by alpha 2(I) collagen.
    Travers H; French NS; Norton JD
    Cell Growth Differ; 1996 Oct; 7(10):1353-60. PubMed ID: 8891339
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Farnesyltransferase and geranylgeranyltransferase I inhibitors upregulate RhoB expression by HDAC1 dissociation, HAT association and histone acetylation of the RhoB promoter.
    Delarue FL; Adnane J; Joshi B; Blaskovich MA; Wang DA; Hawker J; Bizouarn F; Ohkanda J; Zhu K; Hamilton AD; Chellappan S; Sebti SM
    Oncogene; 2007 Feb; 26(5):633-40. PubMed ID: 16909123
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mob-1, a Ras target gene, is overexpressed in colorectal cancer.
    Zhang R; Zhang H; Zhu W; Pardee AB; Coffey RJ; Liang P
    Oncogene; 1997 Apr; 14(13):1607-10. PubMed ID: 9129152
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design and in vivo analysis of potent non-thiol inhibitors of farnesyl protein transferase.
    Anthony NJ; Gomez RP; Schaber MD; Mosser SD; Hamilton KA; O'Neil TJ; Koblan KS; Graham SL; Hartman GD; Shah D; Rands E; Kohl NE; Gibbs JB; Oliff AI
    J Med Chem; 1999 Aug; 42(17):3356-68. PubMed ID: 10464022
    [TBL] [Abstract][Full Text] [Related]  

  • 37. v-Src transformation is mediated through farnesylated proteins.
    Teng S; Sun J; Irby R; Hamilton AD; Sebti S; Yeatman TJ
    J Surg Res; 2001 Aug; 99(2):343-6. PubMed ID: 11469908
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Inhibitors of Ras farnesylation: tomorrow's anticancer agents?].
    Perrin D; Halazy S; Hill B
    Bull Cancer; 1997 Jun; 84(6):635-42. PubMed ID: 9295868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. N-Arylalkyl pseudopeptide inhibitors of farnesyltransferase.
    deSolms SJ; Giuliani EA; Graham SL; Koblan KS; Kohl NE; Mosser SD; Oliff AI; Pompliano DL; Rands E; Scholz TH; Wiscount CM; Gibbs JB; Smith RL
    J Med Chem; 1998 Jul; 41(14):2651-6. PubMed ID: 9651171
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 2-substituted piperazines as constrained amino acids. Application to the synthesis of potent, non carboxylic acid inhibitors of farnesyltransferase.
    Williams TM; Ciccarone TM; MacTough SC; Bock RL; Conner MW; Davide JP; Hamilton K; Koblan KS; Kohl NE; Kral AM; Mosser SD; Omer CA; Pompliano DL; Rands E; Schaber MD; Shah D; Wilson FR; Gibbs JB; Graham SL; Hartman GD; Oliff AI; Smith RL
    J Med Chem; 1996 Mar; 39(7):1345-8. PubMed ID: 8691462
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.